Pulmonary Hypertension in Patients Attending Sohag University Hospital: A Focus on The Etiology

Assessment of pulmonary hypertension in patients attending Sohag university hospital ( in out patient clinic or in patient) focusing on the etiology of pulmonary hypertension

Study Overview

• Status: Recruiting
• Conditions: Patients With Pulmonary Hypertension
• Intervention / Treatment: Other: echocardiography

• Study Type: Observational
• Enrollment (Anticipated): 200

Contacts and Locations

• Study Contact: Name: esraa a saad, assistant lecturer; Phone Number: 002 01065567768; Email: esraa.abdo@med.sohag.edu.eg
• Study Contact Backup: Name: kamal a ata, professor

Study Locations

• Egypt
  • Sohag, Egypt
    • Recruiting
    • Sohag University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

pulmonary hypertension patients attending Sohag university hospital (either admitted in the hospital or attending the out patient clinics)

Description

Inclusion Criteria:

• patients who are 18 years old or more
• patients with pulmonary hypertension diagnosed with echocardiography

Exclusion Criteria:

• patient who are less than 18 years old

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

patients with pulmonary hypertension; patients who are more than 18 years old , diagnosed with pulmonary hypertension by echocardiography

Other: echocardiography; All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.; Other Names: spirometry; CT pulmonary angiography; abdominal ultrasound; electrocardiogram; chest X ray; high resolution Ct chest; arterial blood gases; serological tests e.g Anti nuclear antibodies, anti double stranded DNA antibodies...; right heart catheterization

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Detection of the causes of pulmonary hypertension in patients attending Sohag university hospital	We will diagnose the cause of pulmonary hypertension in each participant. This will be done by following the diagnostic algorithm of European Society of Cardiology/ European Respiratory Society (ESC/ERS) 2015 guidelines (e.g. we will exclude that pulmonary hypertension is secondary to pulmonary disease by performing adequate assessment of the patient medical history and clinical examination, performing chest x-ray and or high resolution CT chest, spirometry...), so we will know the pattern of pulmonary hypertension etiology in patients attending of Sohag university hospital	one year

Collaborators and Investigators

• Sponsor: Sohag University

Publications and helpful links

General Publications

• Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29. Erratum In: Eur Respir J. 2015 Dec;46(6):1855-6.
• Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801913. doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
• Prins KW, Thenappan T. World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. Cardiol Clin. 2016 Aug;34(3):363-74. doi: 10.1016/j.ccl.2016.04.001.

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2021
• Primary Completion (Anticipated): September 1, 2022
• Study Completion (Anticipated): September 1, 2022

Study Registration Dates

• First Submitted: December 29, 2021
• First Submitted That Met QC Criteria: January 12, 2022
• First Posted (Actual): January 26, 2022

Study Record Updates

• Last Update Posted (Actual): January 26, 2022
• Last Update Submitted That Met QC Criteria: January 12, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension; Hypertension, Pulmonary; Physiological Effects of Drugs; Immunologic Factors; Antibodies; Antibodies, Antinuclear
• Other Study ID Numbers: Soh-Med-21-12-20

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No